The audiology diagnostic device, designed to perform gentle, non-invasive middle ear analysis in a matter of seconds, has received approval to be used as a PASS/REFER mode screening device from the first days of infant life, in both paediatrician clinics and on Neonatal Care wards.
The device’s approval follows a clinical trial across six Italian hospitals.
Owen Pemberton, managing director at DP Medical, said: “We’re so excited that med-wave® has been approved for use on babies aged 0-24 months. “The device offers a really quick, pain-free way to assess ear health status and will be an invaluable addition to neonatal care wards and paediatric audiology clinics across the UK and Ireland.”
Based on patented PLAI™ methodology, the device performs a multi-frequency test using a probe that sends chirp signals from 100 to 3000 Hz, that are then analysed at frequencies from 100 to 1500Hz. Med-wave® processes the data collected and compares it with its proprietary database of pathologies in order to offer quick, painless, objective assessment of ear health status.
DP Medical was chosen by Italy-based Neuranix as the exclusive UK and Ireland distributor for the device in 2023.
Commenting on their partnership, Neuranix founder and CEO, Filip Moens, said: “Med-wave’s creation was inspired by my own experience of having multiple painful, invasive and often slow ear tests as a child.
“As I grew up, I thought it must be possible to make this testing equipment more friendly and less invasive. This is why I founded Neuranix – to bring more user and patient friendly test equipment to diagnose and monitor hearing diseases.
“We’re excited to be partnering with DP Medical Systems to bring this innovation and the med-wave device to the UK and Ireland.”
For further information about med-wave® and to arrange a demonstration or purchase through DP Medical, visit www.dpmedicalsys.com/products/audiology/med-wave